Suriyeli ve Türk gebelerin Toksoplazma ve Rubella seropozitifliğinin karşılaştırılması

Yıl 2021, Cilt: 46 Sayı: 3, 975 - 981, 30.09.2021

Gülnur Kul Gökçe Turan

Öz

AAmaç: Toxoplasma gondii, rubella ve sitomegalovirüs (TORCH) enfeksiyonları, özellikle gelişmekte olan ülkelerde perinatal morbidite ve mortalitenin önde gelen nedenleridir. Bu çalışmada bölgemizde artan Suriyeli mülteci gebeler ile Türk gebelerdeki Toxoplasma ve Rubella seroprevelansının karşılaştırılması amaçlanmıştır.
Gereç ve Yöntem: Çalışmamıza Mart 2018-Kasım 2019 tarihleri arasında hastanemize ilk prenatal vizitte başvuran 18-49 yaş arası Suriyeli ve Türk gebeler dahil edildi. Dahil edilen hastaların yaş, gravida, parite, uyruğu ve ilk trimesterdaki anti- T. gondii IgM, anti- T. gondii IgG, anti-Rubella IgM, anti-Rubella IgG sonuçları hastane arşivinden retrospektif olarak kaydedildi ve karşılaştırıldı.
Bulgular: Çalışmaya katılan 3606 gebenin 2768’i (%76,7) Türk, 838’si (%23,3) ise Suriyeli idi. Suriyeli gebelerin anti T. gondii IgM pozitifliği (%6,1), Türk gebelere göre (%2,1) anlamlı olarak daha yüksek bulundu. Anti Rubella IgM pozitifliği her iki grupta benzerdi. Anti rubella IgG ise istatistiksel olarak anlamlı olmamakla birlikte Türk gebelerde daha yüksekti (sırasıyla %85,2 ve %88,7).
Sonuç: Gebe kadınlarda toksoplazma ve rubella enfeksiyonu sıklığı ve yaygınlığı hakkında bilgi sahibi olmak, hastalık yükünün belirlenmesinde, tarama programlarının planlanmasında ve birinci basamak sağlık hizmetlerinin aktif kullanımında kritik bir rol oynamaktadır. Toksoplazma ve rubella gibi doğum öncesi bakımda tarama programları, Suriyeli mülteci sayısının artması dikkate alınarak sağlık hizmeti veren bölgelere özel olarak planlanmalıdır.

Anahtar Kelimeler

gebelik, rubella, seroprevalans, suriyeli mülteciler, toxoplasma gondii

Comparison of Toxoplasma and Rubella seropositivity rates of Syrian and Turkish pregnant women

Öz

Purpose: Toxoplasma gondii, rubella and cytomegalovirus (TORCH) infections are the leading causes of perinatal morbidity and mortality, especially in developing countries. This study aimed to compare the seroprevalence of Toxoplasma and Rubella in Turkish pregnant women and Syrian refugee pregnant women, whose number is increasing in our region.
Materials and Methods: Syrian and Turkish pregnant women between the ages of 18 and 49 who were admitted to a secondary care hospital for their first prenatal visit between March 2018 and November 2019 were included in this retrospective study. Age, gravida, parity, nationality and anti-T. gondii IgM, anti-T. gondii IgG, anti-Rubella IgM, and anti-Rubella IgG test results of the patients included in the study were retrospectively recorded from the hospital archive and compared.
Results: Out of 3,606 pregnant women included in the study, 2,768 (76.7%) were Turkish and 838 (23.3%) were Syrian. Anti-T. gondii IgM positivity rate (6.1%) of Syrian pregnant women was significantly higher than the rate (2.1%) of Turkish pregnant women. Although Anti-Rubella IgG positivity was not statistically significantly different it was higher in Turkish pregnant women (85.2% and 88.7% respectively).
Conclusion: Knowing the incidence and prevalence of toxoplasma and rubella infection in pregnant women plays a critical role in determining the burden of the disease, planning screening programs, and active use of primary healthcare services. Screening programs in antenatal care for toxoplasma and rubella should especially be planned in regions that provide healthcare by considering the increasing number of Syrian refugees.

Anahtar Kelimeler

pregnancy, rubella, seroprevalence, Syrian refugees, toxoplasma gondii

Kaynakça

• 1. Bahat PY, Turan G, Özgör BY, et al. Comparison of hepatitis B, hepatitis C, and HIV seropositivity of Syrian and Turkish pregnant women. Turkish journal of obstetrics and gynecology. 2019;16(2):95.
• 2. Doğan K, Kafkaslı A, Karaman Ü, et al. Gebelerde Toksoplazma enfeksiyonunun seropozitiflik ve serokonversiyon oranları. Mikrobiyol Bul. 2012;46(2):290-294.
• 3. Topçu AW SG, Doğanay M, ed. . Toxoplasma gondii. . İnfeksiyon Hastalıkları ve Mikrobiyolojisi. Vol. 2015. İstanbul: Nobel Tıp Kitabevleri. p. s.1883–97.
• 4. Montoya JG KJ, Remington JS. . Toxoplasma gondii. . Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 6th ed. . Vol. 2005: Philadelphia: Elsevier Churchill Livingstone. p. 3170–98.
• 5. https://gocvakfi.org/tr/2019/11/20/2020-yili-cumhurbaskanligi-yillik-programi-aciklandi/[cited 20.05.2020].
• 6. Cherri Z, Gil Cuesta J, Rodriguez-Llanes JM, et al. Early marriage and barriers to contraception among Syrian refugee women in Lebanon: a qualitative study. International journal of environmental research and public health. 2017;14(8):836.
• 7. CENGİZ SA, CENGİZ L, Ebru U, et al. GEBE KADINLARIN SERUMLARINDA RUBELLA IgG VE IgM’NİN ELISA İLE ARAŞTIRILMASI. İnfeksiyon Dergisi (Turkish Journal of Infection). 2005;19(1):19-24.
• 8. Paquet C, Yudin MH, Allen VM, et al. Toxoplasmosis in pregnancy: prevention, screening, and treatment. Journal of obstetrics and gynaecology Canada. 2013;35(1):78-79.
• 9. SARAÇOĞLU F, ŞAHİN İ. Gebe Populasyonunda Toksoplazma Prevalansı ve Duyarlı Gebelerde Serolojik Dönüşüm Oranı. Journal of Clinical Obstetrics & Gynecology. 2001;11(5):326-328.
• 10. Çiçek AÇ, Duygu F, İnakçı İH, et al. Şanlıurfa ilinde doğurganlık çağındaki kadınlarda ELISA ile Toxoplasma gondii antikorlarının araştırılması: Üç yıllık değerlendirme. J Clin Exp Invest. 2012;3.
• 11. Durukan H, Killi MÇ. Turkiye'de 2012-2017 Yillari Arasinda Ucuncu Basamak Saglik Kurumuna Basvuran Gebe Kadinlarda Toksoplazmozis Seropozitiflik Oraninin ve Klinik Sonuclarin Retrospektif Olarak Degerlendirilmesi/Retrospective Evaluation of the Seropositivity Rate of Toxoplasmosis and Clinical Results in Pregnant Women That were Admitted to a Tertiary Health Institution Between 2012 and 2017 in Turkey. Turkish Journal of Parasitology. 2019;43(3):106-111.
• 12. Thiébaut R, Leproust S, Chêne G, et al. SYROCOT (Sys-tematic Review on Congenital Toxoplasmosis) study group. Effectiveness of prenatal treatment for congenital toxoplas-mosis: a meta-analysis of individual patients’ data. Lancet. 2007;369(9556):115-22.
• 13. https://www.uptodate.com/contents/toxoplasmosis-and-pregnancy?search=toxoplasmosis%20in%20pregnancy&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1.
• 14. Puccio G, Cajozzo C, Canduscio LA, et al. Epidemiology of Toxoplasma and CMV serology and of GBS colonization in pregnancy and neonatal outcome in a Sicilian population. Italian journal of pediatrics. 2014;40(1):23.
• 15. Wong A, Tan K, Tee C, et al. Seroprevalence of cytomegalovirus, toxoplasma and parvovirus in pregnancy. Singapore medical journal. 2000;41(4):151-155.
• 16. de Melo Inagaki AD, de Oliveira LAR, de Oliveira MFB, et al. Seroprevalence of antibodies for toxoplasmosis, rubella, cytomegalovirus, syphilis and HIV among pregnant women in Sergipe. Revista da Sociedade Brasileira de Medicina Tropical. 2009;42(5).
• 17. Pradhan S. Epidemiological and serological profiles of TORCH infection in pregnancy. Journal of Pathology of Nepal. 2015;5(9):705-708.
• 18. Sen M, Shukla B, Tuhina B. Prevalence of serum antibodies to TORCH infection in and around Varanasi, Northern India. Journal of clinical and diagnostic research: JCDR. 2012;6(9):1483.
• 19. Aynioglu A, Aynioglu O, Altunok ES. Seroprevalence of Toxoplasma gondii, rubella and Cytomegalovirus among pregnant females in north-western Turkey. Acta Clinica Belgica. 2015;70(5):321-324.
• 20. Bakacak M, Bostancı MS, Köstü B, et al. Gebelerde Toxoplasma gondii, rubella ve sitomegalovirüs seroprevalansı. Dicle Med J. 2014;41(2):326-31.
• 21. Harma M, Gungen N, Demir N. Toxoplasmosis in pregnant women in Sanliurfa, Southeastern Anatolia City, Turkey. Journal of the Egyptian Society of Parasitology. 2004;34(2):519-525.
• 22. Çoşkun B, Gülümser Ç, Çoşkun B, et al. Impact of Syrian refugees on congenital TORCH infections screening in Turkey. Journal of Obstetrics and Gynaecology Research. 2020.
• 23. Lambert N, Strebel P, Orenstein W, et al. Rubella. The Lancet. 2015;385(9984):2297-2307.
• 24. Glismann S. Rubella in Denmark. Euro surveillance: bulletin Europeen sur les maladies transmissibles= European communicable disease bulletin. 2004;9(4):12-13.
• 25. Davidkin I, Peltola H, Leinikki P. Epidemiology of rubella in Finland. Euro surveillance: bulletin Europeen sur les maladies transmissibles= European communicable disease bulletin. 2004;9(4):13-14.
• 26. Gioula G, Exindari M, Melidou A, et al. Seroprevalence of measles in Northern Greece. Acta Microbiologica Hellenica. 2017;62:145-50.
• 27. Mongua-Rodriguez N, Díaz-Ortega JL, García-García L, et al. A systematic review of rubella vaccination strategies implemented in the Americas: impact on the incidence and seroprevalence rates of rubella and congenital rubella syndrome. Vaccine. 2013;31(17):2145-2151.
• 28. Thayyil J, Kuniyil V, Moorkoth AP, et al. Prevalence of rubella-specific IgG antibodies in unimmunized young female population. Journal of family medicine and primary care. 2016;5(3):658.
• 29. Akpınar O, Akpınar H. Gebe Kadınlarda Rubella ve Sitomegalovirus Seroprevelansının ELISA yöntemi ile Araştırılması. 2017.
• 30. Çetinkaya RA, Yenilmez E. The seroprevalence of Rubella in pregnant women in Turkey: a meta-analysis research of 90988 Rubella IgM, 84398 Rubella IgG, and 522 avidity results. Turkish journal of obstetrics and gynecology. 2019;16(1):63.